Idec, DNA fall on IMS Rituxan numbers

IDPH was down $9.32 (15%) to $52.16 on Thursday, while Genentech (DNA) was off $2.55 to $40.20, after DNA reported after the market close on Wednesday that April IMS sales data for Rituxan were overstated. IMS had said Rituxan sales in April were $62.4 million, and DNA said IMS will not amend the April numbers until August. Nevertheless, sales of Rituxan rituximab for non-Hodgkin's lymphoma increased 83% to $187.7 million from $102.8 million in the second quarter last year. DNA met the Street's second quarter consensus EPS estimate of $0.19 and IDPH, which developed and co-markets Rituxan, said it will meet the Street's second quarter EPS estimate of $0.15. ...